The Transcard Consortium consists of research partners from several European countries aiming at identifying novel targets for cardiovascular disease treatment.
Despite advances in CVD drug development, we are currently still facing a 50-70% residual risk of suffering from CVD, illustrating an urgent need for the identification, characterisation and validation of novel therapeutically relevant targets.
by Jan Albert Kuivenhoven
The project is finalizing its validation of several novel targets, two of which were proposed by Nebion and both yielded a cholesterol phenotype in knock-down or knock-out mice. The target discovery approach used was as follows: